Colorectal

The following list provides a brief description of colorectal cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.

Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.

Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.

 

ZipUP

Registered Title   A single-centre, open-label, phase I study to evaluate the diagnostic performance of 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients
Purpose This trial aims to evaluate the feasibility of using 89Zr-TLX250 PET/CT in the detection of localized and metastatic urothelial carcinoma or bladder cancer.
Lay Summary

It is hoped that information from this trial will help evaluate the effectiveness of 89Zr-TLX250 PET/CT in detecting primary bladder cancer and upper tract urothelial carcinoma."

WA Trial Sites  Oncology Ph. 08 615 26530
Links Australian New Zealand Clinical Trials Registry 

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

SUBDUE-1

Registered Title  A phase 1 open label dose-escalation study to evaluate the tolerability, safety, and immunological efficacy of sub-urothelial durvalumab injection in adult subjects with muscle invasive bladder cancer or high-risk non-muscle invasive bladder tumours.
 Purpose This study aims to evaluate the tolerability and safety of a sub-urothelial injection of durvalumab for Bladder Cancer.
Lay Summary Participants will be allocated to receive a single dose of durvalumab to their bladder. The dose will be decided according to the dose-escalation schedule. Participants will be required to answer a series of questions in regards to their experience whilst receiving care, and consent to their removed tissue being used for this research.

It is hoped this research will provide an alternative, safer and better tolerated treatment option for people with high-risk non-muscle invasive bladder cancer.

WA Trial Sites  Oncology Ph. 08 615 26530
 Links Australian New Zealand Clinical Trials Registry 

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

TRACC

Registered Title   Treatment of Recurrent and Advance Colorectal Cancer (TRACC): A prospective multi-site registry
 Purpose  The primary purpose of this study is to set up a registry of patients with recurrent and advanced colorectal cancer to evaluate patterns in the presentation, treatment and outcomes of the disease. It is for patients over the age of 18. Researchers will collect information relating to the presentation and characteristics of each participant's disease and information on treatments received and response to treatment by reviewing medical records. It is hoped that the findings from the registry will enhance our understanding of how treatments received and the timings of these treatments affect disease outcomes, and how these relate to the presentation and characteristics of colorectal cancers.
Lay Summary  N/A
WA Trial Sites  Oncology Ph. 08 615 26530
 Links Australian New Zealand Clinical Trials Registry 

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

VAPOR-C

Registered Title
 Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
Purpose  VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus sevoflurane) and lidocaine versus placebo on duration of disease free survival inpatients
with either colorectal or non small cell lung cancer.
Lay Summary  N/A
WA Trial Sites   N/A
 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

DYNAMIC -Rectal

Registered Title  Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study (DYNAMIC-RECTAL)
 Purpose  The primary purpose of this study is to show that by using ctDNA results, in addition to assessing the risk of tumour recurrence by standard pathology assessments, the number of patients receiving adjuvant (post surgery) chemotherapy will be reduced.
Lay Summary  It is hoped that the findings from this study will demonstrate that using ctDNA results to help make a decision as to who receives adjuvant chemotherapy will result in a reduction in the number of patients having chemotherapy and doing so, without compromising the rate of disease recurrence when compared to standard of care.
WA Trial Sites  Cancer Centre Clinical Trials Unit Ph. 08 615 26530
 Links  Australian New Zealand Clinical Trials Registry

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

CA224-020

Registered Title    A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
 Purpose The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery.
 Lay Summary  N/A
WA Trial Sites  Linear Clinical Research Ph. 08 6382 5513
 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

ASCOLT Study

Registered Title

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial.

Purpose

We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally..

Lay Summary

N/A

WA Trial Sites

Sir Charles Gairdner Hospital LogoSCGH Medical Oncology  Ph. (08) 6383 3000

Ph. (08) 6465 9204

Links

US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

DYNAMIC III

Registered Title

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study

Purpose The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer.
Lay Summary Who is it for?

You may be eligible to join this study if you are aged 18 years or more and have undergone curative surgery for stage III colon cancer.

Study details
All participants in this study will have a blood draw during week 5-6 post surgery for ctDNA analysis. They will then be randomly allocated to one of two treatment groups. One group will receive standard of care treatment as selected by their clinician: either no chemotherapy, single agent fluoropyrimidine chemotherapy or combination fluoropyrimidine plus oxaliplatin chemotherapy. Treatment selection in the other group will be informed by ctDNA blood test results.

All patients will be followed up every 3 months for 2 years, then every 6 months for 3 years in order to evaluate treatment safety and efficacy. Follow-up involves additional blood tests and radiological assessments. It is hoped that the findings from this study will demonstrate that using ctDNA results to help make a decision regarding adjuvant chemotherapy is not inferior to standard of care in terms of recurrence-free survival.

WA Trial Sites

Cancer Centre Clinical Trials Unit ph. (08) 615 26530

Links  Australian New Zealand Clinical Trials Registry

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

[Return to List of Clinical Trials]